title: Barriers to enrollment of patients with recurrent diffuse large B-cell lymphoma onto clinical trials.
authors: a Department of Hematology , McGill University , Montreal , Quebec , Canada.
authors: Ashley
authors: A
authors: Marton
authors: b Department of Epidemiology , Jewish General Hospital , Montreal , Quebec , Canada.
authors: Abbas
authors: A
authors: Kezouh
authors: c Department of Pathology , Jewish General Hospital , Montreal , Quebec , Canada.
authors: Tina
authors: T
authors: Petrogiannis-Haliotis
authors: d Department of Hematology , Jewish General Hospital , Montreal , Quebec , Canada.
authors: Sarit
authors: S
authors: Assouline
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use; D018450:Disease Progression; D004317:Doxorubicin / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D018579:Patient Selection; D011241:Prednisone / Q000627:therapeutic use; D012107:Research Design; D000069283:Rituximab; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone